Programmed cell death ligand 1 (PD-L1) forms part of the PD-1/PD-L1 pathway exploited by neoplasms to evade immune surveillance, and its inhibition has been shown to be clinically efficacious against a number of cancers (26, 32, 33). Here, CD274 is linked to neoplasm.